- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Submit Revised CT Protocol of FDC Gabapentin,Lidocaine Gel: CDSCO panel tells Akums Drugs
![Submit Revised CT Protocol of FDC Gabapentin,Lidocaine Gel: CDSCO panel tells Akums Drugs Submit Revised CT Protocol of FDC Gabapentin,Lidocaine Gel: CDSCO panel tells Akums Drugs](https://medicaldialogues.in/h-upload/2022/11/26/750x450_192112-akums-pharma-new.webp)
New Delhi: Reviewing the justification and Phase III clinical trial protocol presented by the drug-maker Akums Drugs & Pharmaceuticals for the fixed-dose combination drug Gabapentin USP 6.0% w/w plus Lidocaine HCl IP, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has opined that the firm should submit the revised Phase III clinical trial protocol with respect to exclusion criteria, sample size, rescue medication, etc.
This came after the firm presented the proposal along with justification and the Phase III CT protocol, Gabapentin USP 6.0% w/w plus Lidocaine HCl IP eq. to Lidocaine 5.0% w/w Gel, before the Committee.
The fixed-dose combination drug, Gabapentin USP 6.0% w/w plus Lidocaine HCl IP is used to treat neuropathic pain.
Gabapentin is an anticonvulsant medication used in the management of peripheral neuropathic pain, postherpetic neuralgia, and partial-onset seizures. Gabapentin crosses several lipid membrane barriers via system L amino acid transporters. In vitro, gabapentin modulates the action of the GABA synthetic enzyme, glutamic acid decarboxylase (GAD) and the glutamate synthesizing enzyme, branched-chain amino acid transaminase.
Lidocaine is a local anaesthetic used in a wide variety of superficial and invasive procedures. Lidocaine can block Na+ and K+ ion channels and regulate intracellular and extracellular calcium concentrations through other ligand-gated ion channels. Lidocaine was the first sodium channel blocker to be identified. Its primary mode of action is to block voltage-gated Na+ channels (VGSC/NaVs).
At the recent SEC meeting for Neurology & Psychiatry held on December 16, 2022, the expert panel reviewed the proposal along with justification and the Phase III CT protocol of the FDC Gabapentin USP 6.0% w/w plus Lidocaine HCl IP eq. to Lidocaine 5.0% w/w Gel.
After detailed deliberation, the committee recommended that the firm submit the revised Phase III CT protocol as suggested by experts with respect to exclusion criteria, sample size, rescue medication, etc.
In accordance with the above, the expert panel directed the firm that the revised protocol should be presented before the SEC for further review.
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.